GLP-1 RECEPTOR AGONIST AND USE THEREOF
The present invention provides a novel compound represented by chemical formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The present invention relates to a novel compound exhibiting excellent activity as a GLP-1 receptor agonist. Particularly, the compound accordin...
Gespeichert in:
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre ; kor |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | The present invention provides a novel compound represented by chemical formula 1, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The present invention relates to a novel compound exhibiting excellent activity as a GLP-1 receptor agonist. Particularly, the compound according to the present invention exhibits an excellent effect in a glucose tolerance test through GLP-1 receptor agonist efficacy, thereby exhibiting remarkable effects as an agent for treating metabolic diseases. In addition, from a safety pharmacological perspective, excellent safety for the cardiovascular system is obtained.
La présente invention concerne un nouveau composé représenté par la formule chimique 1, un isomère optique de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci. La présente invention concerne un nouveau composé présentant une excellente activité en tant qu'agoniste du récepteur GLP-1. En particulier, le composé selon la présente invention présente un excellent effet dans un test de tolérance au glucose grâce à son efficacité comme agoniste du récepteur GLP-1, et présente ainsi des effets remarquables en tant qu'agent pour le traitement de maladies métaboliques. En outre, d'un point de vue de la pharmacologie d'innocuité, une excellente innocuité pour le système cardiovasculaire est obtenue.
본 발명은 신규의 화학식 1로 표시되는 화합물, 이의 광학 이성질체, 또는 이들의 약제학적으로 허용가능한 염을 제공한다. 본 발명은 신규 화합물로써 GLP-1 수용체 작용제로서 뛰어난 활성을 나타낸다. 특히, 본 발명에 따른 화합물은 GLP-1 수용체 작용제로의 효과를 통해 내당능 평가에서 우수한 효과를 나타내어 대사성 질환에 대한 치료제로 현저한 효과를 나타낸다. 더욱이, 안전성 약리 측면에서 심혈관계에 대한 우수한 안전성을 확인하였다. |
---|